Related content

Pharmacokinetics of Venlafaxine Extended Release 75 mg and Desvenlafaxine 50 mg in Healthy CYP2D6 Extensive and Poor Metabolizers: A Randomized, Open-Label, Two-Period, Parallel-Group, Crossover Study

By Nichols Alice I.  

Clinical Drug Investigation, Vol. 31, Iss. 3, 2011-03 ,pp. : 155-167

Adis International

Access to resources Recommend Favorite

Finasteride 1 mg has no inhibitory effect on omeprazole metabolism in extensive and poor metabolizers for CYP2C19 in Japanese

By Yasumori T.   Narita H.   Matsuda T.   Takubo T.   Ogawa M.   Ishii M.   Hara K.   Ishii Y.   Okuyama K.   Fujimoto G.   Ochiai H.   Kano A.   Hasegawa S.   Sato K.   Taniguchi T.  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 11, 2006-11 ,pp. : 939-946

Springer Publishing Company

Access to resources Recommend Favorite

[ 3 H]GBR 12935 binding in platelets from poor and extensive cytochrome P-4502D6 metabolizers

By Norlen M.   Norstrom A.   Spigset O.   Allard P.  

European Journal of Pharmacology, Vol. 366, Iss. 2, 1999-02 ,pp. : 329-332

Elsevier

Access to resources Recommend Favorite

The effect of Shoseiryuto, a traditional Japanese medicine, on cytochrome P450s, N-acetyltransferase 2 and xanthine oxidase, in extensive or intermediate metabolizers of CYP2D6

By Nakao Masashi   Muramoto Yousuke   Hisadome Motoko   Yamano Naoko   Shoji Mami   Fukushima Yumi   Saruwatari Junji   Nakagawa Kazuko  

European Journal of Clinical Pharmacology, Vol. 63, Iss. 4, 2007-04 ,pp. : 345-353

Springer Publishing Company

Access to resources Recommend Favorite

Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics

By Sehrt Daniel   Meineke Ingolf   Tzvetkov Mladen   Güültepe Senol   Brockmööller Jüürgen  

Pharmacogenomics, Vol. 12, Iss. 6, 2011-06 ,pp. : 783-795

Future Medicine

Access to resources Recommend Favorite